ARTICLE | Clinical News
Pradaxa: Completed Ph III enrollment
November 30, 2016 4:16 PM UTC
Boehringer completed enrollment of 2,727 patients in the open-label, international Phase III RE-DUAL PCI trial comparing 110 and 150 mg oral Pradaxa twice daily plus clopidogrel or Brilinta ticagrelor...
BCIQ Company Profiles
BCIQ Target Profiles